open access

Ahead of print
Review Article
Published online: 2020-11-09
Get Citation

Antiplatelet effects of prostacyclin analogues: which one to choose in case of thrombosis or bleeding?

Sylwester P. Rogula, Hubert M. Mutwil, Aleksandra Gąsecka, Marcin Kurzyna, Krzysztof J. Filipiak
DOI: 10.5603/CJ.a2020.0164
·
Pubmed: 33200814

open access

Ahead of print
Review articles
Published online: 2020-11-09

Abstract

Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension (PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their potency and form of administration, they might also inhibit platelets to a different extent. This review summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an individual patients’ needs.

Abstract

Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension (PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their potency and form of administration, they might also inhibit platelets to a different extent. This review summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an individual patients’ needs.

Get Citation

Keywords

prostacyclin analogues, pulmonary arterial hypertension, platelets, antiplatelet effect, thrombosis, bleeding

About this article
Title

Antiplatelet effects of prostacyclin analogues: which one to choose in case of thrombosis or bleeding?

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Review Article

Published online

2020-11-09

DOI

10.5603/CJ.a2020.0164

Pubmed

33200814

Keywords

prostacyclin analogues
pulmonary arterial hypertension
platelets
antiplatelet effect
thrombosis
bleeding

Authors

Sylwester P. Rogula
Hubert M. Mutwil
Aleksandra Gąsecka
Marcin Kurzyna
Krzysztof J. Filipiak

References (57)
  1. Von Euler US. Über die Spezifische Blutdrucksenkende Substanz des Menschlichen Prostata- und Samenblasensekretes. Klin Wochenschr. 1935; 14(33): 1182–1183.
  2. The Nobel Prize. https://www.nobelprize.org/prizes/medicine/1982/press-release/ (Accessed: 7 April 2020).
  3. Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011; 63(3): 471–538.
  4. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010; 104(1): 9–21.
  5. Safdar Z. Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. Respir Med. 2011; 105(6): 818–827.
  6. Uptravi® Full Prescribing Information. https://www.uptravi.com/assets/pdf/UPTRAVI-full-prescribing-information.pdf (Accessed 7 April 2020).
  7. Heemskerk JWM, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost. 2002; 88(2): 186–193.
  8. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014; 58(5): 515–523.
  9. Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Lab Med. 2017; 48(4): 295–313.
  10. Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can J Anaesth. 2006; 53(6 Suppl): S2–11.
  11. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008; 31(4): 891–901.
  12. Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther. 1996; 72(3): 171–191.
  13. Boie Y, Sawyer N, Slipetz DM, et al. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem. 1995; 270(32): 18910–18916.
  14. Deep A, Zoha M, Dutta Kukreja P. Prostacyclin as an anticoagulant for continuous renal replacement therapy in children. Blood Purif. 2017; 43(4): 279–289.
  15. Boie Y, Rushmore TH, Darmon-Goodwin A, et al. Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem. 1994; 269(16): 12173–12178.
  16. Berridge MJ. Inositol trisphosphate and calcium signaling. Nature. 1993; 361(6410): 315–325.
  17. Hirata M, Hayashi Y, Ushikubi F, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991; 349(6310): 617–620.
  18. Nagy Z, Smolenski A. Cyclic nucleotide-dependent inhibitory signaling interweaves with activating pathways to determine platelet responses. Res Pract Thromb Haemost. 2018; 2(3): 558–571.
  19. Chakraborty R, Pydi SP, Gleim S, et al. New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling. Mol Cell Biol. 2013; 33(2): 184–193.
  20. Kotani M, Tanaka I, Ogawa Y, et al. Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics. 1997; 40(3): 425–434.
  21. Sitbon O, Channick R, Chin K, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26): 2522–2533.
  22. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000; 1483(2): 285–293.
  23. Kiriyama M, Ushikubi F, Kobayashi T, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997; 122(2): 217–224.
  24. Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007; 322(3): 1181–1188.
  25. Whittle BJ, Silverstein AM, Mottola DM, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012; 84(1): 68–75.
  26. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005; 172(12): 1586–1589.
  27. Chin KM, Channick RN, de Lemos JA, et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009; 135(1): 130–136.
  28. Hargett C, Ahearn G, Krichman A, et al. Thrombocytopenia associated with chronic intravenous epoprostenol therapy. Chest. 2004; 126(4).
  29. Ogawa A, Matsubara H, Fujio H, et al. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy. Circ J. 2005; 69(2): 216–220.
  30. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334(5): 296–301.
  31. Herrero T, Martin E, Poch DS, et al. Anti-coagulation complications in pregnancies with severe pulmonary arterial hypertension. J Matern Fetal Neonatal Med. 2018; 31(9): 1209–1213.
  32. Louis L, Bair N, Banjac S, et al. Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs [corrected]. Pulm Circ. 2012; 2(4): 518–521.
  33. Ascha M, Zhou X, Rao Y, et al. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil. Cardiovasc Ther. 2017; 35(5).
  34. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006; 28(6): 1195–1203.
  35. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6): 800–804.
  36. Mindus S, Pawlowski J, Nisell M, et al. Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension. BMJ Case Rep. 2013; 2013.
  37. Ferdman DJ, Rosenzweig EB, Zuckerman WA, et al. Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy. Pediatrics. 2014; 134(1): e274–e278.
  38. Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019; 7(3): 239–248.
  39. Kurzyna M, Małaczyńska-Rajpold K, Koteja A, et al. An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil. BMC Pulm Med. 2017; 17(1): 162.
  40. Bajwa AA, Shujaat A, Patel M, et al. The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Pulm Circ. 2017; 7(1): 82–88.
  41. Bettoni L, Geri A, Airò P, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol. 2002; 21(3): 244–250.
  42. de Donato G, Gussoni G, de Donato G, et al. The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery. Ann Surg. 2006; 244(2): 185–193.
  43. Eifinger F, Sreeram N, Mehler K, et al. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin Padiatr. 2008; 220(2): 66–69.
  44. Chen S, Xie S, He W, et al. Beneficial effect of beraprost sodium plus aspirin in the treatment of acute ischemic stroke. Med Sci Monit. 2017; 23: 4401–4407.
  45. Kim M, Kim JiU, Kim SoMi, et al. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis. Int Urol Nephrol. 2017; 49(7): 1287–1295.
  46. Krause A, Machacek M, Lott D, et al. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. CPT Pharmacometrics Syst Pharmacol. 2017; 6(7): 477–485.
  47. Bruderer S, Hurst N, Kaufmann P, et al. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014; 94(3-4): 148–156.
  48. Stitham J, Arehart E, Gleim SR, et al. New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues. Br J Pharmacol. 2007; 152(4): 513–522.
  49. Wright DH, Metters KM, Abramovitz M, et al. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998; 123(7): 1317–1324.
  50. Flolan® Full Prescribing Information. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Flolan/pdf/FLOLAN-PI-PIL.PDF (Accessed 7 April 2020).
  51. Veletri® Full Prescribing Information. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/VELETRI-pi.pdf (Accessed 7 April 2020).
  52. Orenitram® Full Prescribing Information. https://www.orenitram.com/pdf/Orenitram_Full_Prescribing_Information.pdf (Accessed 7 April 2020).
  53. Remodulin® Full Prescribing Information. https://www.remodulin.com/downloads/remodulin-prescribinginformation.pdf (Accessed 7 April 2020).
  54. Tyvaso® Full Prescribing Information. https://www.tyvaso.com/hcp/pdf/Tyvaso-PI.pdf (Accessed 7 April 2020).
  55. Ventavis® Full Prescribing Information. https://www.4ventavis.com/pdf/Ventavis_PI.pdf (Accessed 7 April 2020).
  56. Melian EB1, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002; 62(1): 107–133.
  57. Kingman M, Archer-Chicko C, Bartlett M, et al. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017; 7(3): 598–608.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl